Emerging therapies in rosacea - 13/11/13
Abstract |
Rosacea is a common skin disorder with multiple symptoms. The emergence of research that furthers understanding of pathophysiological mechanisms has created new targets for disease treatment. Specifically, there is a need for new treatments that address the various erythematic symptoms associated with rosacea. Systemic and topical therapies have both yielded positive results in treating rosacea with various medications. Subantimicrobial-dose doxycycline is one such promising treatment. Development of novel products in the near future should help achieve more satisfactory outcomes for patients.
Le texte complet de cet article est disponible en PDF.Key words : carvedilol, ivermectin, medical therapy, permethrin, rosacea, subantimicrobial-dose doxycycline
Abbreviation used : SDD
Plan
Publication of this article was supported by a grant from Galderma International. Editorial support provided by Galderma International. |
|
Disclosure: Dr Layton has served on advisory boards for Galderma, GSK, Meda, and Intendis and served on the board of directors for PCOS UK, and received honoraria as compensation. Dr Thiboutot has served as a consultant for Allergan, Galderma, Medicis, Photocure, Stiefel, and Valeant, and received honoraria as compensation. |
Vol 69 - N° 6S1
P. S57-S65 - décembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?